AI Insight
Researchers developed a computational model that simulates bone loss in postmenopausal women by incorporating genetic variants, hormonal regulation, and cellular signaling pathways involved in bone remodeling. The model, calibrated on clinical data and tested on 1,000 virtual subjects with different genetic profiles, predicted a median 5-year bone mineral density loss of 3.57%, consistent with published literature. Key genetic risk factors identified include CYP19A1 rs727479 and OPG rs3102735 variants, while LRP5 rs11228240 appeared protective, with the model suggesting estrogen primarily affects bone remodeling through osteoclast apoptosis.
Why it matters
This mechanistic framework could enable personalized prediction of osteoporosis risk based on individual genetic profiles and ancestry, potentially allowing earlier intervention and tailored treatment strategies. The approach demonstrates how genetic data can be integrated into disease models beyond bone health, offering a template for studying other complex conditions with polygenic inheritance.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Bone remodeling is a tightly regulated physiological process that maintains bone health through coordinated action of bone-resorbing osteoclasts and bone-forming osteoblasts. Disruption of this balance, such as the one induced by estrogen decline after menopause, results in bone loss and osteoporosis. Genetic factors play an important role in determining bone mineral density (BMD) loss over time. However, translating genetic associations into individualized risk prediction remains challenging due to small effect size of individuals variants and non-linear interactions within the bone remodeling unit. Here, we present a bone cell population dynamics model that includes major regulatory pathways, such as the RANK/RANKL/OPG axis, Wnt signaling, and hormonal regulation by estrogen, parathyroid hormone, and TGF-{beta}. We calibrate the model on clinical data from healthy postmenopausal women, and women with reduced BMD undergoing anti-osteoporotic therapy. The calibrated model captures healthy BMD decline in postmenopausal women and therapeutic response to anti-osteoporotic medications. We mechanistically incorporate the effect of 22 variants across 8 genes involved in bone remodeling and simulate BMD trajectories in 1,000 virtual subjects differing by ancestry and genetic makeup. The median predicted 5-year BMD loss was 3.57% (95% prediction interval: 1.31-5.24), consistent with the values reported in the literature. The virtual individuals with African ancestry were predicted to experience the highest average 5-year BMD loss. The strongest genetic risk factors for bone loss were predicted to be CYP19A1 rs727479 and OPG rs3102735, while LRP5 rs11228240 emerged as a protective factor that could partially counteract the detrimental effects of other variants. Several epistatic effects were observed in the genetic interaction analysis. Mechanistically, our model suggested that estrogen exerts its effect on bone remodeling primarily by modulating osteoclast apoptosis. Overall, this framework demonstrates a proof-of-concept for integration of genetic risk factors into mechanistic models of disease and can be extended to other conditions with polygenic inheritance.
Source: A mechanistic model for genetic regulation of postmenopausal bone loss